Inactivation of the Hutchinson strain of hepatitis non-A, non-B virus in intravenous immunoglobulin by beta-propiolactone.

Abstract

beta-propiolactone (beta-PL) treatment has been evaluated for its ability to inactivate 10(3.5) chimpanzee infectious doses (CID50) of the Hutchinson strain of hepatitis non-A, non-B virus (HNANBV). Two chimpanzees were inoculated with a beta-PL-treated immunoglobulin solution to which this dose of the titrated virus had been added prior to beta-PL treatment. beta-PL treatment was performed in accordance with the production procedure used for a licensed intravenous immunoglobulin preparation. Neither animal developed hepatitis. When subsequently challenged with the same spiked immunoglobulin solution that had not been beta-PL treated, both animals developed clear-cut hepatitis non-A, non-B. The results of this experiment demonstrate that beta-PL treatment is effective for the inactivation of hepatitis non-A, non-B virus in intravenous immunoglobulin.

• Authors: W Stephan, H Dichtelmüller, A M Prince, B Brotman, T Huima
• Journal: Journal of medical virology (J Med Virol) Vol. 26 Issue 3 Pg. 227-32 (Nov 1988) ISSN: 0146-6615 [Print] United States
• PMID: 3144576 (Publication Type: Journal Article)

Chemical References

• Antiviral Agents
• Immunoglobulins
• Lactones
• Propiolactone

Topics

• Animals
• Antiviral Agents
• Drug Contamination
• Drug Evaluation, Preclinical
• Female
• Hepatitis C (prevention & control, transmission)
• Hepatitis Viruses (drug effects)
• Hepatitis, Viral, Human (prevention & control)
• Immunoglobulins (administration & dosage, adverse effects)
• Injections, Intravenous
• Lactones (pharmacology)
• Pan troglodytes
• Propiolactone (pharmacology)